Lenacapavir: New Injectable HIV Drug Offers 96-100% Efficacy with Twice-Yearly Dosing, Recognized as Scientific Breakthrough

Dec 30, 2024, 01:30 PM

A new injectable antiretroviral drug, Lenacapavir, has been recognized as a potential breakthrough in the fight against HIV and AIDS. According to reports, it boasts an efficacy rate of 96-100% and offers a twice-yearly dosing schedule, which could significantly enhance treatment accessibility and adherence. This innovation has been highlighted by the journal 'Science' as a scientific breakthrough of the year, with the potential to curb new HIV infections globally. Discussions around its availability and implementation are ongoing, as stakeholders consider the implications of this advancement in HIV prevention and treatment.